CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
Items 801–900 of 1,010
Yu, M., D’Amelio, P., Tyagi, A. M., Vaccaro, C., Li, J., Hsu, E., Buondonno, I., Sassi, F., Adams, J., Weitzmann, M. N., et al. (2017) · EMBO Reports · doi:10.15252/embr.201744421 · Cited by 74
Foxp1 is critical for the maintenance of regulatory T-cell homeostasis and suppressive function
Ren, J., Han, L., Tang, J., Liu, Y., Deng, X., Liu, Q., Hao, P., Feng, X., Li, B., Hu, H., et al. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000270 · Cited by 74
Regulatory T Cells Suppress Effector T Cell Proliferation by Limiting Division Destiny
Dowling, M. R., Kan, A., Heinzel, S., Marchingo, J. M., Hodgkin, P. D., & Hawkins, E. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02461 · Cited by 73
“Here, no difference is observed in the first entry of responding cells into division; (2) The rate of division (the gradient of the mean division number vs.”
BackgroundJin, F., Liu, D., Xu, X., Ji, J., & Du, Y. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s314506 · Cited by 73
Belatacept: from rational design to clinical application
Wekerle, T., & Grinyo, J. M. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01386.x · Cited by 73
“CTLA-4 is important for the function of regulatory T cells (Tregs) on which it is constitutively expressed [39] and is involved in inducing a specific form of anergy [40,41].”
BackgroundExpanding role of T cells in acute kidney injury
Kinsey, G. R., & Okusa, M. D. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000436695.29173.de · Cited by 73
“Through CTLA-4, Tregs interact with dendritic cells to downregulate costimulatory molecule expression, and thus inhibit their ability to promote inflammation [69].”
BackgroundArruda, L. C. M., de Azevedo, J. T. C., de Oliveira, G. L. V., Scortegagna, G. T., Rodrigues, E. S., Palma, P. V. B., Brum, D. G., Guerreiro, C. T., Marques, V. D., Barreira, A. A., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.06.005 · Cited by 73
“We show that AHSCT promotes significant, albeit short-lived, expansion of peripheral CD4+CD25highFoxp3+ Tregs from 6 to 36 months post-transplantation.”
Teh, C. E., Lalaoui, N., Jain, R., Policheni, A. N., Heinlein, M., Álvarez-Díaz, S., Sheridan, J. M., Rieser, E., Deuser, S., Darding, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13353 · Cited by 73
Tallerico, R., Cristiani, C. M., Staaf, E., Garofalo, C., Sottile, R., Capone, M., de Coaña, Y. P., Madonna, G., Palella, E., Wolodarski, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1261242 · Cited by 74
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 75
Immune checkpoint inhibitor-related myocarditis
Tajiri, K., Aonuma, K., & Sekine, I. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx154 · Cited by 73
“These results suggest that CTLA-4 deficiency in Tregs alone suffices to cause myocarditis; however, the additional CTLA-4 deficiency in conventional T cells enhances the disease (29,30).”
BackgroundSurface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 75
“Genetic ablation of CTLA-4 on Treg cells results in fatal autoimmunity and is sufficient to induce tumor regression in some models (20).”
BackgroundAge-Related Changes in Thymic Central Tolerance
Srinivasan, J., Lancaster, J. N., Singarapu, N., Hale, L. P., Ehrlich, L. I. R., & Richie, E. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.676236 · Cited by 75
Advancing age leads to predominance of inhibitory receptor expressing CD4 T cells☆
Channappanavar, R., Twardy, B. S., Krishna, P., & Suvas, S. (2009) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2009.08.006 · Cited by 73
Pharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury
Lai, L.-W., Yong, K.-C., & Lien, Y.-H. H. (2011) · Kidney International · doi:10.1038/ki.2011.412 · Cited by 72
“Wing et al.(21) demonstrated that Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs and causes systemic lymphoproliferation, fatal T cell–mediated autoimmune disease, and hyperproduction of IgE in mice.”
InfluentialPido-Lopez, J., Kwok, W. W., Mitchell, T. J., Heyderman, R. S., & Williams, N. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002396 · Cited by 72
Abnormal CTLA‐4 function in T cells from patients with systemic lupus erythematosus
Jury, E. C., Flores‐Borja, F., Kalsi, H. S., Lazarus, M., Isenberg, D. A., Mauri, C., & Ehrenstein, M. R. (2010) · European Journal of Immunology · doi:10.1002/eji.200939781 · Cited by 72
Advances on CD8+ Treg Cells and Their Potential in Transplantation
Bézie, S., Anegón, I., & Guillonneau, C. (2018) · Transplantation · doi:10.1097/tp.0000000000002258 · Cited by 73
Regulatory T Cells: From Discovery to Autoimmunity
Kitz, A., Singer, E. R., & Hafler, D. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029041 · Cited by 74
“Through CTLA4 ligation of CD80 and CD86, FoxP3+ Tregs can modulate DC function, thereby inhibiting DC costimulation of effector T cells (Wing et al. 2008).”
BackgroundThe interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era
Spyrou, N., Vallianou, N. G., Kadillari, J., & Dalamaga, Μ. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.008 · Cited by 73
Therapeutic potential of interleukin-2 in autoimmune diseases
Yuan, Y., Kolios, A. G. A., Liu, Y., Zhang, B., Li, H., Tsokos, G. C., & Zhang, X. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.010 · Cited by 72
Adult-onset autoimmune diabetes
Buzzetti, R., Maddaloni, E., Gaglia, J. L., Leslie, R. D., Wong, F. S., & Boehm, B. O. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00390-6 · Cited by 71
Multimodal single cell-resolved spatial proteomics reveal pancreatic tumor heterogeneity
Xu, Y., Wang, X., Li, Y., Mao, Y., Su, Y., Mao, Y., Yang, Y., Gao, W., Fu, C., Chen, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54438-0 · Cited by 71
Tissue resident regulatory T cells: novel therapeutic targets for human disease
Zhou, X., Tang, J., Cao, H., Fan, H., & Li, B. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.23 · Cited by 73
Schmidt, A., Oberle, N., Weiss, E., Vobis, D., Frischbutter, S., Baumgrass, R., Falk, C. S., Haag, M., Brügger, B., Lin, H., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2002179 · Cited by 71
Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition
Brzostek, J., Gascoigne, N. R. J., & Rybakin, V. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00024 · Cited by 72
“Stimulated TCR-transgenic Tregs specifically reduce expression of both CD80 and CD86 on DC and to lesser degree B cells (84, 87, 161, 162).”
BackgroundImmuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials
Kudo, M. (2019) · Liver Cancer · doi:10.1159/000501501 · Cited by 71
Physiological basis for xenotransplantation from genetically modified pigs to humans
Peterson, L., Yacoub, M. H., Ayares, D., Yamada, K., Eisenson, D. L., Griffith, B. P., Mohiuddin, M. M., Eyestone, W. H., Venter, J. C., Smolenski, R. T., et al. (2024) · Physiological Reviews · doi:10.1152/physrev.00041.2023 · Cited by 72
Regulatory T Cell Dysfunction in Autoimmune Diseases
Honing, D. Y., Luiten, R. M., & Matos, T. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137171 · Cited by 72
“Studies in mice have shown that CTLA-4 is essential for the suppressive function of FoxP3 + Tregs while LAG-3 is required for maximal Treg activity in vitro and in vivo [12,13].”
BackgroundLü, Y., Xiao, J., Wu, Z.-W., Wang, Z., Hu, J., Fu, H., Chen, Y., & Qian, R. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.04.010 · Cited by 70
The Role of the LAT–PLC-γ1 Interaction in T Regulatory Cell Function
Chuck, M. I., Zhu, M., Shen, S., & Zhang, W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902876 · Cited by 70
“(23) demonstrated that although the expression of CTLA-4 on regulatory T cells is not necessary for Treg cell development and survival, it is essential for both their”
BackgroundInfluentialMonoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies
Bhandaru, M., & Rotte, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_4 · Cited by 70
CCL22 Signaling in the Tumor Environment
Röhrle, N., Knott, M. M. L., & Anz, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36667-4_8 · Cited by 72
Kohlhapp, F. J., Broucek, J. R., Hughes, T. M., Huelsmann, E. J., Lusciks, J., Zayas, J. P., Dolubizno, H., Fleetwood, V. A., Grin, A., Hill, G. R., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0063-3 · Cited by 69
“Tregs suppress CD8+ T cell and NK cell responses specifically through CTLA-4 [35] and by acting as IL-2 sinks through expression of high levels of the high affinity IL-2 receptor, CD25 [36].”
BackgroundRegulatory T Cells Require TCR Signaling for Their Suppressive Function
Schmidt, A. M., Lu, W., Sindhava, V. J., Huang, Y., Burkhardt, J. K., Yang, E., Riese, M. J., Maltzman, J. S., Jordan, M. S., & Kambayashi, T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402384 · Cited by 58
“Because Tregs constitutively express CTLA-4 and require this molecule to mediate suppression (53, 54), perhaps CTLA-4 is sufficient to induce cellular adhesion in the ADAP KO and/or Crk/CrkL DKO setting.”
BackgroundPedroza‐González, A., Zhou, G., Singh, S. P., Boor, P. P. C., Pan, Q., Grünhagen, D. J., de Jonge, J., Tran, T. K., Verhoef, C. K., IJzermans, J. N. M., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1051297 · Cited by 71
Gannavaram, S., Bhattacharya, P., Ismail, N., Kaul, A., Singh, R. K., & Nakhasi, H. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00187 · Cited by 71
“It has been proposed that blocking CTLA-4 might dampen the IL-10-mediated suppressive effects since CTLA-4 is very highly expressed on Treg cells (84).”
BackgroundEFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis
Walker, L. S. K. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.007 · Cited by 69
Regulatory T cells in acute and chronic kidney diseases
Sharma, R., & Kinsey, G. R. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00236.2017 · Cited by 69
Low-dose chidamide restores immune tolerance in ITP in mice and humans
Zhao, H., Ma, Y., Li, D.-Q., Sun, T., Li, L.-Z., Li, P., Liu, X., Zhou, H., Hou, Y., Liu, Y., et al. (2018) · Blood · doi:10.1182/blood-2018-05-847624 · Cited by 69
Morris, G. P., Brown, N. K., & Kong, Y.-C. M. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.03.010 · Cited by 69
Kudo, M. (2019) · Liver Cancer · doi:10.1159/000496277 · Cited by 69
The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation
Blank, C. U. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000054 · Cited by 68
Mayer, C. T., Berod, L., & Sparwasser, T. D. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00183 · Cited by 70
“Notably, the disruption of CTLA-4 signals can abrogate the suppressive function of Tregs in vivo (Sakaguchi et al., 2008; Wing et al., 2008).”
The Role of Coinhibitory Signaling Pathways in Transplantation and Tolerance
McGrath, M. M., & Najafian, N. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00047 · Cited by 68
“…University, Japan *Correspondence: Nader Najafian, Transplantation Research Center, Brigham and Women’s Hospital and Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA. e-mail: nnajafian@rics.bwh. harvard.edu Negative costimulatory molecules, acting through so-called inhibitory…”
BackgroundICOS Regulates the Generation and Function of Human CD4+ Treg in a CTLA-4 Dependent Manner
Zheng, J. H., Chan, P., Liu, Y., Qin, G., Xiang, Z., Lam, K.-T., Lewis, D. B., Lau, Y., & Tu, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082203 · Cited by 68
“mediated suppression both in vivo and in vitro [39-41].”
BackgroundNurieva, R., Wang, J., & Sahoo, A. (2013) · Immunotherapy · doi:10.2217/imt.13.33 · Cited by 71
Disrupted regulatory T cell homeostasis in inflammatory bowel diseases
Pedros, C., Duguet, F., Saoudi, A., & Chabod, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.974 · Cited by 69
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 70
“[19] Unlike effector cells, Tregs express CTLA-4 constitutively and acts as a major mechanism of suppression by Tregs.[20] CTLA-4 on Tregs competes with CD28 on effector T cells for binding with CD80/86 on APCs, thus suppressing T cell activation.”
CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells
Hornero, R. A., Georgiadis, C., Peng, H., Trzupek, D., He, L.-Z., Qasim, W., Todd, J. A., Ferreira, R. C., Wood, K. J., Issa, F., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1097-8 · Cited by 72
Teh, C. E., Daley, S. R., Enders, A., & Goodnow, C. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009209107 · Cited by 67
Schlöder, J., Shahneh, F. Z., Schneider, F.-J., & Wieschendorf, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.973813 · Cited by 67
“CTLA-4 has a higher affinity to bind its costimulatory molecules CD80 (B7-1) and CD86 (B7-2) on DC, thereby interfering with the binding of CD28 in Teff, thus diminishing DC’s capacity to activate T cells (50, 51).”
BackgroundCombination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 69
The confluence of radiotherapy and immunotherapy
Burnette, B., Fu, Y., & Weichselbaum, R. R. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00143 · Cited by 68
“In addition, Tregs constitutively express CTLA-4, which has been shown to directly control DC maturation and the induction of T cell tolerance by downregulating B7-1/B7-2 expression on DCs to block the CD28:B7-1/B7-2 signal (Wing et al., 2008; Qureshi et al., 2011).”
BackgroundImmune Checkpoint Therapy for Non-Small-Cell Lung Cancer: An Update
Xia, B., & Herbst, R. S. (2016) · Immunotherapy · doi:10.2217/imt.15.123 · Cited by 69
How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?
Liu, Y., & Zheng, P. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.009 · Cited by 67
“lineage-specific deletion of mouse Ctla4 in Tregs alone is sufficient to largely recapitulate the fatal lymphoproliferative diseases associated with germline mutations in the Ctla4 gene [12], which argues that CTLA-4 primarily functions in Tregs.”
BackgroundAntibody-mediated targeting of TNFR2 activates CD8 + T cells in mice and promotes antitumor immunity
Tam, E. M., Fulton, R. B., Sampson, J. F., Muda, M., Camblin, A. J., Richards, J. M. J., Koshkaryev, A., Tang, J., Kurella, V. B., Jiao, Y., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0720 · Cited by 67
The regulation of CD4+ T cells during malaria
Kumar, R., Loughland, J. R., Ng, S. S., Boyle, M. J., & Engwerda, C. R. (2019) · Immunological Reviews · doi:10.1111/imr.12804 · Cited by 71
Hargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 67
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Aziz, M. A. A. E., Facciorusso, A., Nayfeh, T., Saadi, S. M., Elnaggar, M. Y., Cotsoglou, C., & Sacco, R. (2020) · Vaccines · doi:10.3390/vaccines8040616 · Cited by 67
“Based on this, several studies have shown promising results with dual immunotherapy [34,35].”
BackgroundPlatelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
Kuratani, A., Okamoto, M., Kishida, K., Okuzaki, D., Sasai, M., Sakaguchi, S., Arase, H., & Yamamoto, M. (2024) · Science · doi:10.1126/science.adn8608 · Cited by 67
Self-citationBoor, P. P. C., Metselaar, H. J., de Jonge, S., Mancham, S., van der Laan, L. J. W., & Kwekkeboom, J. (2011) · European Journal of Immunology · doi:10.1002/eji.201041229 · Cited by 66
Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management
Shirabe, K., Motomura, T., Muto, J., Toshima, T., Matono, R., Mano, Y., Takeishi, K., Ijichi, H., Harada, N., Uchiyama, H., et al. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-010-0131-0 · Cited by 66
“The possible mechanisms include (a) Tregs secrete immunosuppressive cytokines, such as tumor growth factor (TGF)-b, interleukin (IL)-10, and IL-35 [26, 27]; (b) Tregs inhibit T-cell activation-dependent receptor (TCR) production of IL-2 and interferon (IFN)-c [28, 29]; and (c) Tregs suppress antigen-presenting cells (…”
BackgroundHsu, L.-H., Li, K.-P., Chu, K., & Chiang, B. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.56 · Cited by 66
Miska, J. M., Abdulreda, M. H., Devarajan, P., Lui, J. B., Suzuki, J., Pileggi, A., Berggren, P., & Chen, Z. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20130785 · Cited by 66
“Contact interaction between Treg and Teff cells with or without CD11c+ DCs Treg cells can dampen the expression of the co-stimulatory molecules CD80 and CD86 on the surface of DCs, and thus inhibit T cell activation (Shevach, 2008; Wing et al., 2008).”
BackgroundInfluentialJeffery, L. E., Qureshi, O. S., Gardner, D. H., Hou, T. Z., Briggs, Z., Soskic, B., Baker, J., Raza, K., & Sansom, D. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131539 · Cited by 66
“In support of this hypothesis and our finding that Th17 conditions suppress CTLA-4 in FoxP3+ as well as FoxP3- T cells, a number of in-vivo studies have reported reduced CTLA-4 expression on Tregs and non-Tregs from patients with inflammatory disease [47–49].”
InfluentialVille, S., Poirier, N., Branchereau, J., Charpy, V., Pengam, S., Nerrière‐Daguin, V., Bas‐Bernardet, S. L., Coulon, F., Mary, C., Chenouard, A., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015070774 · Cited by 66
Ronin, É., Pouchy, C., Khosravi, M., Hilaire, M., Grégoire, S., Casrouge, A., Kassem, S., Sleurs, D., Martin, G. H., Chanson, N., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014043118 · Cited by 66
“S5C), which are markers of effector Treg cells (1, 23, 24).”
BackgroundIncreased Number of Regulatory T Cells in Children With Eosinophilic Esophagitis
Fuentebella, J., Patel, A., Nguyen, T., Sanjanwala, B. M., Berquist, W. E., Kerner, J. A., Bass, D. M., Cox, K. L., Hurwitz, M., Huang, J. J., et al. (2010) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3181e0817b · Cited by 66
“Cytotoxic T-lymphocyte antigen 4 (CTLA4 or CD152) transmits inhibitory signals to T cells and is also found in Treg (10,14,15).”
BackgroundLelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
“CTLA-4 is constitutively expressed on Tregs and contributes to their regulatory and immunosuppressive action through multiple mechanisms (82, 83).”
BackgroundSpatiotemporal regulation of peripheral T cell tolerance
Brown, C. C., & Rudensky, A. Y. (2023) · Science · doi:10.1126/science.adg6425 · Cited by 65
Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies
Wang, X., He, J. N., Ding, G., Tang, Y., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688699 · Cited by 66
“Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) is upregulated on T cells shortly after initial activation in lymphoid organs and is expressed constitutively on regulatory T cells (Tregs) (25).”
Regulatory T Cells: Banned Cells for Decades
Loser, K., & Beissert, S. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.375 · Cited by 65
“Thus, CTLA-4 deficiency in Tregs alone was sufficient to abrogate its suppressor function (Wing et al., 2008; Shevach, 2009).”
BackgroundDavies, M. N., Bayry, J., Tchilian, E. Z., Vani, J., Shaila, M. S., Forbes, E. K., Draper, S. J., Beverley, P. C. L., Tough, D. F., & Flower, D. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008084 · Cited by 65
“While elucidating all the diverse mechanisms by which Tregs inhibit immune responses remains a subject of active investigation, a principal means in which they function is through interaction with antigen-presenting dendritic cells (DC) [10–13].”
BackgroundRadiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges
Goto, T. (2019) · Vaccines · doi:10.3390/vaccines7030100 · Cited by 66
“Blocking CTLA-4 enhances T-cell activation, increasing the ratio of CD8+ T cells to regulatory T cells [143] and thereby strengthening the in situ vaccination effect (Figure 1) [142].”
BackgroundPrecision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
Ortiz‐Cuaran, S., Bouaoud, J., Karabajakian, A., Fayette, J., & Saintigny, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.614332 · Cited by 65
CXCL-10: a new candidate for melanoma therapy?
Bagheri, H., Pourhanifeh, M. H., Derakhshan, M., Mahjoubin‐Tehran, M., Ghasemi, F., Mousavi, S., Rafiei, R., Abbaszadeh‐Goudarzi, K., Mirzaei, H. R., & Mirzaei, H. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00501-z · Cited by 65
“By expressing CTLA-4, FOXp3 Treg cells counter immunostimulatory functions of the B7–1 andB7–2 (CD80/CD86) receptors which are expressed on antigen presenting cells [80].”
BackgroundOur current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 66
Reactive oxygen species formation and its effect on CD4+ T cell-mediated inflammation
Shu, P., Liang, H., Zhang, J., Lin, Y., Chen, W., & Zhang, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199233 · Cited by 66
Tang, Y., Cui, G., Liu, H., Han, Y., Cai, C., Feng, Z., Shen, H., & Zeng, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12546 · Cited by 66
Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma
Sarnaik, A. A., & Weber, J. S. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181a7450f · Cited by 64
Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis
Di Giovangiulio, M., Rizzo, A., Franzè, E., Caprioli, F., Facciotti, F., Onali, S., Favale, A., Stolfi, C., Fehling, H.-J., Monteleone, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02158 · Cited by 63
van Pul, K. M., Notohardjo, J. C. L., Fransen, M. F., Koster, B. D., Stam, A. G. M., Chondronasiou, D., Lougheed, S. M., Bakker, J., Kandiah, V., van den Tol, M. P., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8097 · Cited by 63
Tanoue, T., & Honda, K. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.11.009 · Cited by 65
“Interestingly, large subset of Treg cells induced by the colonization of Clostridum spp. expressed high levels of IL-10 and CTLA-4 [17], which re required for Treg-induced suppression of immune responses. herefore, Clostridium spp. may influence the qualitative properies of colonic Treg cells, as well as their quantit…”
BackgroundInfluentialRegulation Generation: The Suppressive Functions of Human Regulatory T Cells
Goodman, W. A., Cooper, K. D., & McCormick, T. S. (2012) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v32.i1.40 · Cited by 63
Verhagen, J., Genolet, R., Britton, G. J., Stevenson, B. J., Sabatos-Peyton, C. A., Dyson, J., Luescher, I. F., & Wraith, D. C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208573110 · Cited by 63
Induction and stability of the anergic phenotype in T cells
Valdor, R., & Macián, F. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.010 · Cited by 64
Lee, S.-Y., Cho, M., Oh, H., Ryu, J., Park, M., Jhun, J., Park, M., Stone, J. C., Ju, J., Hwang, S., et al. (2012) · Immunology · doi:10.1111/imm.12008 · Cited by 65
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis
Soskic, B., Jeffery, L. E., Kennedy, A., Gardner, D. H., Hou, T. Z., Halliday, N., Williams, C., Janman, D., Rowshanravan, B., Hirschfield, G. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577655 · Cited by 62
“One intriguing observation is that Treg cells appear to specifically express the highest affinity CTLA-4 ligand, CD80, whilst at the same time relying on CTLA-4 for suppressive function (10, 29).”
BackgroundDixit, N., Fanton, C. P., Langowski, J. L., Kirksey, Y. M., Kirk, P. B., Chang, T., Cetz, J., Dixit, V., Kim, G., Kuo, P., et al. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100103 · Cited by 63
CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis
Xu, X., Dennett, P., Zhang, J., Sherrard, A., Zhao, Y., Masubuchi, T., Bui, J. D., Chen, X., & Hui, E. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221391 · Cited by 62
“CTLA4 hypofunction results in autoimmunity, while its high expression is associated with immunosuppression and restricted T cell function in cancer and chronic viral infection (Attanasio and Wherry, 2016; Kuehn et al., 2014; Wing et al., 2008).”
Clinical Outlook for Type-1 and FOXP3+ T Regulatory Cell-Based Therapy
Gregori, S., Passerini, L., & Roncarolo, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00593 · Cited by 62
“Previous trials based on the adoptive transfer of alloAgs-specific anergic T cells generated in vitro in the presence of Belatacept (CTLA-4-Ig) to prevent GvHD after allo-HSCT were performed (56, 57).”
BackgroundInfluentialCD28 blockade controls T cell activation to prevent graft-versus-host disease in primates
Watkins, B. K., Tkachev, V., Furlan, S. N., Hunt, D. J., Betz, K., Yu, A., Brown, M., Poirier, N., Zheng, H. B., Taraseviciute, A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98793 · Cited by 62
Low, J. L., Walsh, R. J., Ang, Y. L. E., Chan, G. H. J., & Soo, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919870360 · Cited by 62
Hong, E., & Dobrovolskaia, M. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.005 · Cited by 63
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 61
Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective
Amini, L., Kaeda, J., Fritsche, E., Roemhild, A., Kaiser, D., & Reinke, P. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1081644 · Cited by 61
“CTLA-4 blocks co-stimulation reducing CD80/CD86 expression and this triggers IDO upregulation.”
BackgroundInfluentialLax, B. M., Palmeri, J. R., Lutz, E. A., Sheen, A. M., Stinson, J. A., Duhamel, L., Santollani, L., Kennedy, A., Rothschilds, A. M., Spranger, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300895120 · Cited by 61
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.